{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/009/SRR6395519/SRR6395519_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/001/SRR6395531/SRR6395531_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/003/SRR6395533/SRR6395533_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/007/SRR6395527/SRR6395527_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/006/SRR6395526/SRR6395526_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/001/SRR6395521/SRR6395521_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/002/SRR6395532/SRR6395532_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/002/SRR6395532/SRR6395532_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/000/SRR6395520/SRR6395520_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/001/SRR6395531/SRR6395531_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/003/SRR6395533/SRR6395533_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/000/SRR6395530/SRR6395530_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/008/SRR6395518/SRR6395518_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/009/SRR6395529/SRR6395529_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/008/SRR6395528/SRR6395528_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/009/SRR6395529/SRR6395529_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/008/SRR6395528/SRR6395528_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/003/SRR6395523/SRR6395523_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/005/SRR6395525/SRR6395525_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/004/SRR6395524/SRR6395524_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/000/SRR6395530/SRR6395530_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/002/SRR6395522/SRR6395522_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/008/SRR6395518/SRR6395518_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/009/SRR6395519/SRR6395519_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/003/SRR6395523/SRR6395523_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/004/SRR6395524/SRR6395524_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/006/SRR6395526/SRR6395526_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/002/SRR6395522/SRR6395522_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/007/SRR6395527/SRR6395527_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/005/SRR6395525/SRR6395525_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/000/SRR6395520/SRR6395520_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR639/001/SRR6395521/SRR6395521_1.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Walter and Eliza Hall Institute of Medical Research"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA423168"],"scientific_name":["Mus musculus"],"long_description":["Using an acute myeloid leukemia (AML) mouse model driven by tet-regulated MLL-AF9 (fusion between the gene MLL1 (KMT2A/MLL) and MLLT3 (AF9)) co-expressed with oncogenic NRASG12D (Tet-off MLL-AF9), we investigated the effect of modulating the expression of the MLL-AF9 fusion oncogene on the transcriptome and proteome of established murine AML. Treatment in vitro or in vivo of these Tet-off MLL-AF9 AMLs with doxycycline (DOX) results in the efficient down-regulation of the expression of the driver oncogene MLL-AF9. RNA sequencing analysis was performed on primary Tet-Off MLL-AF9 AML cells obtained from the spleen of leukemic animals and cultured in vitro for either 2 or 4 days in the presence of doxycycline (1μg/ml) (DOX= down-regulation of MLL-AF9) or left untreated (UT). Overall design: Primary murine acute myeloid leukemias (Tet-off MLL-AF9 AML) driven by the doxycycline-reversible (Tet-OFF) expression of the oncogenic fusion protein MLL-AF9 linked to dsRED reporter, in association with oncogenic NRASG12D (Tet-off MLL-AF9) were generated by reconstituting lethally irradiated congenic mice with foetal liver cells co-transduced with a Tet-Off-MLL-AF9-dsRED retroviral vector and a second vector co-expressing NRASG12D together with the Tet-Off responsive transcriptional activator. Four primary Tet-Off MLL-AF9 leukemias obtained from the spleen of terminally sick animals were cultured in vitro in the presence of doxycycline (1μg/ml) or left untreated. The RNA was collected at day 2 and 4 after the start of the doxycycline treatment. Total RNA extraction was performed using Trizol reagent (Invitrogen) according to the manufacturer’s instructions. RNA-seq libraries were prepared from 400 ng of total RNA using the Illumina Truseq V2 RNA-seq kit. Paired-end 50bp RNA-seq short reads were generated using HiSeq2500. 4 biological replicates (UT vs DOX) are provided for each of the 2 timepoints."],"repository":["ENA"],"description_synonyms":["Myelogenous Leukemias, Myelocytic, HTRX1, Tet, Acute Myeloblastic, 4aalpha, acute myeloblastic leukemia, BMY28689, Nonlymphocytic Leukemia, acute non lymphoblastic leukemia, Myeloid, Doxycycline Calcium, acute myeloblastic leukaemia, doxycycline, acute myelogenous leukaemia, NS6, Supracyclin, Myelocytic Leukemia, MLL|GAS7, Vibramycin Novum, Doxycycline-Chinoin, 2-Naphthacenecarboxamide, 12A-PENTAHYDROXY-6-METHYL-1, thymoma, nap, Downregulation, MLL1A, Acute Myeloid, BU-3839T, Cxxc7, BU 3839T, 10, Acute Myelocytic Leukemias, Hydramycin, 11, 12, Down Regulation., 2610012I03Rik, 5AR, acute non lymphoblastic leukaemia, Doxycycline Chinoin, Alpha-6-Deoxyoxytetracycline, ALPS4, Acute Myelocytic, Acute Nonlymphoblastic, Whole Transcriptome Shotgun Sequencing, Vibra-Tabs, 4, acute myeloid, 5, 6, Doxycycline Calcium Salt (1:2), Myeloblastic Leukemia, adult, NCMS, N-ras, Leukemia, 6alpha, Acute Myelogenous, Acute Myeloblastic Leukemia, Doxycycline Hyclate, ALL-1, Myelogenous Leukemia, mak, Acute Nonlymphocytic Leukemias, Mll1, MLL1, Acute Myeloid Leukemia without Maturation, 11-DIOXO-1, Alpha 6 Deoxyoxytetracycline, 4AR, doxycyclinum, (4S-(4alpha, 6430520K01, Acute Nonlymphoblastic Leukemia, Acute Nonlymphocytic Leukemia, Jenacyclin, Myeloid Leukemia, Myelocytic Leukemias, ANLL, Doryx, YEATS3, Nonlymphoblastic Leukemias, 3830408D16Rik, 12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE, acute myelogenous, leukemia, Myelogenous, Oracea, M1, 2210011H10Rik, M2, 12a-octahydro-3, MLE, Doxycycline Monohydrate, acute myelogenous leukemia, doxiciclina, Periostat, NRAS1, Doxycycline Hemiethanolate, Mll, MLL, 4A, Vibravenos, HRX, RNA-seq, Af9, Doxycycline Phosphate (1:1), CG11680, MLL/GAS7, BMY-28689, Leukemias, Atridox, 5-hydroxy-alpha-6-deoxytetracycline, AML, BMY 28689, Acute Myelocytic Leukemia, Nonlymphoblastic Leukemia, Nonlymphocytic Leukemias, Nonlymphoblastic, Down-Regulation, Acute Myeloid Leukemias, 5aalpha, Receptor Down-Regulation, DmelCG11680, mll, 5A, Down-Regulation (Physiology), 4a, Af-9, Myeloid Leukemias, CMNS, 5alpha, AF9, mls, Acute Nonlymphocytic, 6alpha-deoxy-5-oxytetracycline, Acute Myelogenous Leukemia, 5S, TET1-MLL, acute, Acute myelogenous leukemia, Vibra Tabs, (4S, D4Ertd321e, Myeloblastic, Vibramycin, 12aalpha))-, 5a, CXXC7, All1, WDSTS, susceptibility to, Dihydrate, Myeloblastic Leukemias, NRAS, 11-dioxo-, Acute Myeloid Leukemia, acute myeloid leukemia, acute myeloid leukaemia, 12a-pentahydroxy-6-methyl-1, doxycycline (anhydrous), Nonlymphocytic, mKIAA4050, 6R, 6 epimer, 6-epimer, Acute Myeloid Leukemia with Maturation, Doxycyclin, Acute, BU3839T, nap[ts], Acute Nonlymphoblastic Leukemias, Acute Myeloblastic Leukemias, 4-(dimethylamino)-1, Acute Myelogenous Leukemias, TRX1, Receptor, AV095280, 12AS)-4-(DIMETHYLAMINO)-3, AML - acute Myeloid Leukemia, Doxycycline Monohydrochloride"],"name_synonyms":["Myelogenous Leukemias, Myelocytic, HTRX1, Tet, Acute Myeloblastic, 4aalpha, acute myeloblastic leukemia, BMY28689, Nonlymphocytic Leukemia, acute non lymphoblastic leukemia, Myeloid, Doxycycline Calcium, acute myeloblastic leukaemia, doxycycline, acute myelogenous leukaemia, NS6, Supracyclin, Myelocytic Leukemia, MLL|GAS7, Vibramycin Novum, Doxycycline-Chinoin, 2-Naphthacenecarboxamide, 12A-PENTAHYDROXY-6-METHYL-1, thymoma, nap, Downregulation, MLL1A, Acute Myeloid, BU-3839T, Cxxc7, BU 3839T, 10, Acute Myelocytic Leukemias, Hydramycin, 11, 12, Down Regulation., 2610012I03Rik, 5AR, acute non lymphoblastic leukaemia, Doxycycline Chinoin, Alpha-6-Deoxyoxytetracycline, ALPS4, Acute Myelocytic, Acute Nonlymphoblastic, Whole Transcriptome Shotgun Sequencing, Vibra-Tabs, 4, acute myeloid, 5, 6, Doxycycline Calcium Salt (1:2), Myeloblastic Leukemia, adult, NCMS, N-ras, Leukemia, 6alpha, Acute Myelogenous, Acute Myeloblastic Leukemia, Doxycycline Hyclate, ALL-1, Myelogenous Leukemia, mak, Acute Nonlymphocytic Leukemias, Mll1, MLL1, Acute Myeloid Leukemia without Maturation, 11-DIOXO-1, Alpha 6 Deoxyoxytetracycline, 4AR, doxycyclinum, (4S-(4alpha, 6430520K01, Acute Nonlymphoblastic Leukemia, Acute Nonlymphocytic Leukemia, Jenacyclin, Myeloid Leukemia, Myelocytic Leukemias, ANLL, Doryx, YEATS3, Nonlymphoblastic Leukemias, 3830408D16Rik, 12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE, acute myelogenous, leukemia, Myelogenous, Oracea, M1, 2210011H10Rik, M2, 12a-octahydro-3, MLE, Doxycycline Monohydrate, acute myelogenous leukemia, doxiciclina, Periostat, NRAS1, Doxycycline Hemiethanolate, Mll, MLL, 4A, Vibravenos, HRX, RNA-seq, Af9, Doxycycline Phosphate (1:1), CG11680, MLL/GAS7, BMY-28689, Leukemias, Atridox, 5-hydroxy-alpha-6-deoxytetracycline, AML, BMY 28689, Acute Myelocytic Leukemia, Nonlymphoblastic Leukemia, Nonlymphocytic Leukemias, Nonlymphoblastic, Down-Regulation, Acute Myeloid Leukemias, 5aalpha, Receptor Down-Regulation, DmelCG11680, mll, 5A, Down-Regulation (Physiology), 4a, Af-9, Myeloid Leukemias, CMNS, 5alpha, AF9, mls, Acute Nonlymphocytic, 6alpha-deoxy-5-oxytetracycline, Acute Myelogenous Leukemia, 5S, TET1-MLL, acute, Acute myelogenous leukemia, Vibra Tabs, (4S, D4Ertd321e, Myeloblastic, Vibramycin, 12aalpha))-, 5a, CXXC7, All1, WDSTS, susceptibility to, Dihydrate, Myeloblastic Leukemias, NRAS, 11-dioxo-, Acute Myeloid Leukemia, acute myeloid leukemia, acute myeloid leukaemia, 12a-pentahydroxy-6-methyl-1, doxycycline (anhydrous), Nonlymphocytic, mKIAA4050, 6R, 6 epimer, 6-epimer, Acute Myeloid Leukemia with Maturation, Doxycyclin, Acute, BU3839T, nap[ts], Acute Nonlymphoblastic Leukemias, Acute Myeloblastic Leukemias, 4-(dimethylamino)-1, Acute Myelogenous Leukemias, TRX1, Receptor, AV095280, 12AS)-4-(DIMETHYLAMINO)-3, AML - acute Myeloid Leukemia, Doxycycline Monohydrochloride"],"additional_accession":[]},"is_claimable":false,"name":"RNA-seq profiling of murine Tet-off MLL-AF9 NRAS acute myeloid leukemia at different timepoints upon doxycycline-induced MLL-AF9 down-regulation.","description":"RNA-seq profiling of murine Tet-off MLL-AF9 NRAS acute myeloid leukemia at different timepoints upon doxycycline-induced MLL-AF9 down-regulation.","dates":{"last_updated":"2025-09-24","first_public":"2022-01-01"},"accession":"PRJNA423168","cross_references":{"GEO":["GSE108326"],"taxon":["10090"]}}